Replimune Group Incorporated has secured another regulatory review for RP1, its tumour-injected oncolytic immunotherapy for patients with advanced melanoma whose cancer has progressed after treatment containing a PD-1 inhibitor.
The United States Food and Drug Administration has accepted the latest Biologics License Application resubmission as a complete Class 1 response and set August 2, 2026, as its target action date. The agency has also informed Replimune that it should expect an advisory committee meeting in late July, creating a public examination of RP1’s efficacy evidence, trial design and benefit-risk profile shortly before the decision.
The unusually short review gives Replimune a third opportunity to obtain accelerated approval after the FDA rejected the programme in July 2025 and again on April 10, 2026. However, acceptance for review does not mean the agency has resolved its concerns or become convinced that RP1 works.
The central question remains unchanged. Replimune has reported durable tumour responses and encouraging long-term survival among patients treated with RP1 and nivolumab, but the principal IGNYTE study was a single-arm trial that could not clearly separate the contribution of RP1 from the checkpoint inhibitor used alongside it.
Why has the FDA accepted another RP1 resubmission only weeks after rejecting the same application?
The latest acceptance follows renewed discussions between Replimune and senior FDA leadership after the April complete response letter. The company said in May that both sides had aligned on a path for reconsideration and that the agency intended to treat the resubmission as an urgent matter because patients with advanced melanoma have limited options after PD-1 therapy fails.
A Class 1 designation normally applies to a resubmission that the agency believes can be reviewed within a relatively short period. The August 2 target date arrives little more than a month after the June 26 acceptance announcement, far faster than the six-month timeline generally associated with a more substantial Class 2 resubmission.
That speed may indicate that the FDA is reconsidering an existing evidence package rather than reviewing a newly completed pivotal trial. Replimune has not disclosed results from a mature new randomised study capable of replacing IGNYTE as the primary basis for approval.
The company has added longer-term survival data, additional analyses and information from its ongoing confirmatory programme. Those updates may strengthen the argument that responses are durable and clinically meaningful, but they do not automatically solve the FDA’s earlier concern that the treatment effect was not established through an adequate and well-controlled investigation.
The advisory committee is therefore likely to carry unusual weight. The panel may be asked whether RP1’s response rate, duration of response, safety profile and unmet need provide enough confidence for accelerated approval despite limitations that would ordinarily require randomised evidence.
What exactly did the FDA reject when it issued two complete response letters for RP1?
The first complete response letter, dated July 21, 2025, concluded that the Phase 2 IGNYTE study was not an adequate and well-controlled clinical investigation capable of providing substantial evidence of effectiveness.
The study evaluated RP1 together with nivolumab in adults with unresectable advanced cutaneous melanoma that had progressed after PD-1-based therapy. It did not include a concurrent control group, meaning every participant received the investigational combination.
The FDA identified three broad problems. It questioned whether the response rate could be interpreted reliably across a heterogeneous patient population, whether historical studies provided an appropriate comparison and whether the trial could determine how much of the observed activity came from RP1 rather than nivolumab.
Replimune resubmitted the application in October 2025 with additional analyses and early information from its randomised Phase 3 IGNYTE-3 study. The FDA accepted that resubmission but issued another complete response letter in April 2026.
The second rejection was more detailed. The agency said the early Phase 3 analysis included only 40 patients, representing about 10% of the planned 400-person study. It also noted that tumour responses had been assessed only by investigators at that stage, duration-of-response data were limited and certain progression-free survival analyses had not been prespecified with adequate statistical controls.
The FDA therefore maintained that neither the original single-arm evidence nor the small early randomised dataset provided the substantial evidence required for approval.
Why did tumour injection and response assessment become such important regulatory issues?
RP1 is injected directly into selected tumours. This creates a challenge when objective response rate is used as the primary measure of activity because local treatment can shrink or destroy the lesions receiving the injection.
The FDA reported that almost half of the patients classified as responders in IGNYTE had all their target lesions injected. When patients without non-injected target lesions were also considered, more than half of the reported responders lacked a suitable non-injected target lesion through which a systemic anti-tumour effect could be evaluated.
That does not mean the responses were clinically irrelevant. A patient can benefit when an injected tumour disappears or shrinks. The regulatory problem is determining whether RP1 generated a broader immune response capable of controlling cancer throughout the body, rather than producing only a local effect where the virus was administered.
The agency also identified cases in which lesions were reinjected after enlargement or the appearance of new disease but before an independent review committee had confirmed progression. That sequence could complicate the calculation of both response rate and duration of response.
Surgical procedures and excisional biopsies created another concern. Removing tumour tissue can reduce the measurable size of a lesion, making it difficult to determine how much of a subsequent response reflects drug activity and how much results from the intervention itself.
Replimune has argued that detailed analyses found no material response difference between injected and non-injected lesions and that surgical procedures did not drive the reported outcomes. The advisory committee will have to determine whether those retrospective explanations sufficiently address the FDA’s methodological concerns.
How strong are the IGNYTE clinical results supporting accelerated approval of RP1?
The IGNYTE melanoma cohort included approximately 140 patients with confirmed progression after anti-PD-1-based therapy. Replimune reported an independently assessed objective response rate of 33.6%, including a complete response rate of 15%.
The median duration of response reached 24.8 months, while approximately 44.8% of responders remained in response at three years. The company’s updated survival analysis found a median overall survival of 32.9 months, with 47.8% of all treated participants alive at the three-year point.
Among patients who responded to treatment, 83.5% were alive at three years. That observation supports the view that responses can be deep and durable, although responder-based survival analyses must be interpreted carefully because patients who achieve a response are inherently a selected group with better outcomes.
The safety profile has generally appeared manageable. Replimune reported mainly mild or moderate constitutional effects such as fever, chills and fatigue, with no treatment-related Grade 5 events identified in the long-term analysis.
These findings explain why melanoma investigators and patient advocates have supported access to RP1. A one-third response rate with prolonged response duration would be clinically meaningful in a population whose disease has already progressed after modern immunotherapy.
The unresolved issue is not whether some patients experienced substantial tumour regression. It is whether the study design allows regulators to conclude reliably that RP1 caused the additional benefit and that the magnitude is sufficient to predict clinical advantage over existing options.
Can the three-year survival update repair weaknesses in the original single-arm study?
Long-term survival data can strengthen an oncology application when they show that tumour responses translate into durable patient outcomes. A median overall survival of nearly 33 months in heavily treated advanced melanoma is encouraging and supports the argument that the activity is not merely temporary radiographic shrinkage.
However, overall survival in a single-arm trial remains difficult to interpret. Patients may differ in disease burden, prior treatment, subsequent therapy, performance status and other prognostic factors. Without a randomised comparator, researchers cannot determine precisely what survival would have occurred without RP1.
Cross-trial comparisons are also vulnerable to differences in enrolment criteria and treatment history. The post-PD-1 melanoma population is particularly heterogeneous because some patients progress rapidly during initial therapy, while others relapse after an extended response or after receiving treatment in an adjuvant setting.
The FDA previously concluded that the historical literature did not provide a sufficiently well-matched benchmark for establishing RP1’s effect. The updated survival analysis does not remove that limitation, although it may increase confidence that the reported responders experienced genuine and durable benefit.
The advisory panel will therefore need to decide whether the total evidence is compelling enough for a conditional approval while the randomised confirmatory trial continues.
How does RP1 attempt to turn an injected herpes virus into a systemic cancer treatment?
RP1, also known as vusolimogene oderparepvec, is based on an engineered strain of herpes simplex virus type 1. It is designed to replicate selectively within tumours, destroy cancer cells and release tumour antigens that can alert the immune system.
The virus has been modified to express a fusogenic protein known as GALV-GP R minus. This feature is intended to cause infected tumour cells to fuse, increasing local tumour destruction and the immunogenicity of cell death.
RP1 also expresses granulocyte-macrophage colony-stimulating factor, which is intended to support the recruitment and activation of immune cells around the tumour.
Nivolumab blocks the PD-1 immune checkpoint. The combination is designed to create tumour-specific immune activity through RP1 and then prevent cancer from suppressing that response through the PD-1 pathway.
The strategy is scientifically plausible. Local injection may convert the treated tumour into a source of antigens and immune stimulation, while nivolumab allows activated T cells to attack disease elsewhere.
The regulatory challenge is demonstrating that systemic component convincingly. A treatment administered directly into a tumour must show that it produces effects beyond the injected lesion if it is to become a broadly useful systemic therapy for advanced cancer.
Would RP1 fill a meaningful treatment gap after PD-1 therapy has stopped working?
Advanced melanoma treatment has improved substantially through checkpoint inhibitors, targeted therapies and cellular immunotherapy. Nevertheless, a considerable proportion of patients either fail to respond to PD-1 therapy or eventually experience disease progression.
Treatment choices after checkpoint failure depend on prior therapy, mutation status, disease distribution, performance status and the availability of specialised centres.
RP1 could provide a differentiated option for patients with accessible injectable lesions. The treatment does not require the personalised cell manufacturing, lymphodepleting chemotherapy and intensive supportive care associated with tumour-infiltrating lymphocyte therapy.
However, intratumoural administration creates its own practical limitations. Patients need lesions that can be reached safely through direct injection or image-guided procedures, and repeated treatment may require coordination among oncologists, surgeons, radiologists and specialised nursing teams.
RP1 would therefore not become the correct choice for every patient with advanced melanoma. Its commercial and clinical position would depend on the approved label, the number of eligible injectable lesions, comparative effectiveness and how easily treatment can be incorporated into oncology centres.
The combination also requires nivolumab, making it important to demonstrate that reintroducing or continuing PD-1 blockade adds value after prior PD-1-containing therapy has failed.
Why is separating RP1’s contribution from nivolumab central to the FDA’s decision?
Combination products must generally provide evidence that each active component contributes to the observed treatment effect. This prevents patients from being exposed to an additional drug, procedure or toxicity without proof that the added component provides benefit.
IGNYTE did not include an RP1-alone arm or a nivolumab-alone control arm. The trial therefore showed what happened after patients received the combination but could not directly measure the contribution of either component.
Replimune argues that nivolumab alone would not be expected to generate the observed response rate in patients whose disease had already progressed during PD-1 therapy. It also believes the biological mechanism and responses in non-injected lesions support RP1’s contribution.
The FDA has taken a stricter position. It said differences among patients and the lack of a reliable control made it difficult to determine whether nivolumab rechallenge, RP1 or the interaction between the two produced the responses.
The ongoing randomised IGNYTE-3 programme was intended to provide confirmatory evidence, but its original design also attracted FDA questions. The control group includes treatments selected by physicians, and the agency previously questioned whether the design and statistical assumptions would isolate RP1’s contribution adequately.
The late-July panel discussion may reveal whether the agency is willing to accept the existing biological and clinical rationale temporarily, subject to a revised and enforceable confirmatory-trial commitment.
What does the planned FDA advisory committee mean for Replimune’s approval chances?
An advisory committee meeting is neither an approval nor a rejection. Independent experts will review the evidence publicly, question the company and FDA reviewers, and vote on one or more questions established by the agency.
The panel is likely to examine whether IGNYTE’s objective responses are reliable, whether duration and survival support clinical meaningfulness, whether RP1’s contribution has been established and whether uncertainty can be addressed through post-approval studies.
The meeting could also explore the consequences of delaying access until a full randomised trial is completed. Patients whose melanoma progresses after PD-1 therapy may deteriorate quickly, and some available alternatives are complex or unsuitable.
A favourable vote would strengthen the case for accelerated approval but would not bind the FDA. An unfavourable vote would make an August approval significantly harder, although the agency can reach a different conclusion from its advisers.
The very decision to convene a panel indicates that the dispute is substantive. The FDA is not simply completing an administrative review. It is preparing for a public scientific discussion about whether RP1 meets the evidentiary standard for accelerated approval.
How has the RP1 regulatory reversal changed investor sentiment toward Replimune shares?
Replimune shares were trading near $10.94 on June 26, giving the company a market capitalisation of approximately $1 billion. The stock slipped modestly after the acceptance announcement, suggesting that the review itself had already been anticipated.
The larger revaluation occurred after Replimune disclosed on May 29 that the FDA had agreed to reconsider the application. The shares closed at $4.60 on May 26 and subsequently rose above $11, meaning the stock more than doubled within approximately one month.
The shares remained below the 52-week high of approximately $13.24 but far above the April low of $1.50 reached after the second complete response letter.
This movement shows that investors now assign a materially higher probability to approval than they did after the April rejection. It does not imply confidence that approval is assured.
The short review period creates a concentrated binary catalyst. A positive advisory vote and approval could support commercial launch expectations and restore confidence in the broader RPx oncolytic immunotherapy platform. Another rejection could reopen questions about restructuring, manufacturing costs, cash runway and whether RP1 must wait for mature Phase 3 results.
Near-term sentiment is therefore optimistic but highly speculative. The market has priced in the existence of a third chance, while the advisory committee and August 2 decision will determine whether that opportunity becomes a commercial product.
Could the FDA approve RP1 while still requiring stronger confirmatory evidence?
Accelerated approval allows the FDA to authorise therapies for serious conditions based on an endpoint considered reasonably likely to predict clinical benefit. Sponsors must then complete confirmatory studies to verify the anticipated benefit.
RP1’s response rate and duration of response could potentially support that framework if the FDA accepts that the measurements are reliable and meaningfully exceed what would be expected from available treatment.
Approval could be accompanied by a narrow patient population, detailed post-marketing requirements and a firm timeline for completing a randomised trial. The agency may also require changes to IGNYTE-3 to address control-arm, endpoint and statistical concerns.
This path would provide earlier access while preserving the ability to withdraw the indication if confirmatory evidence failed. It would also place substantial operational pressure on Replimune to complete the study despite the availability of the therapy commercially.
The difficulty is that accelerated approval still requires persuasive evidence. It is not intended to replace the requirement to establish that a treatment is active. The advisory committee must decide whether IGNYTE’s limitations create manageable uncertainty or prevent reliable interpretation altogether.
Has anything scientifically decisive changed since the FDA rejected RP1 in April?
The most visible new clinical information is the longer-term survival analysis showing that nearly half of treated patients remained alive at three years and that responses continued to be durable.
That strengthens the overall benefit narrative but does not constitute the controlled trial requested in the April complete response letter. Replimune has not announced a mature randomised dataset establishing RP1’s effect against physician-selected treatment.
The more significant change may be the FDA’s willingness to reassess how much uncertainty is acceptable in a high-unmet-need setting. That is a regulatory judgement rather than a new scientific result.
RP1 has a plausible and clinically interesting activity profile, but the FDA’s earlier methodological objections were substantial rather than technical. The agency documented specific issues involving injected lesions, reinjection, surgical procedures, historical comparisons and the contribution of nivolumab.
Approval would therefore require the new review team and advisory committee to conclude that response durability, survival, safety and unmet need collectively outweigh those deficiencies.
That is possible under accelerated approval, particularly if the confirmatory programme is redesigned and enforceable. It is not the same as showing that the earlier concerns were incorrect.
What should clinicians and investors watch before the August 2 RP1 decision?
The advisory committee briefing documents will be the most informative next disclosure. They should reveal the precise voting question, the FDA’s latest interpretation of the data and whether the agency believes the previous deficiencies have been adequately addressed.
Attention will also focus on how the updated survival data are analysed, whether the FDA accepts responses in non-injected lesions as evidence of systemic activity and whether newer IGNYTE-3 information contributes meaningfully to the application.
The proposed confirmatory-trial plan will matter almost as much as the existing data. A credible randomised study with appropriate controls, independent review and achievable enrolment could make regulators more comfortable granting conditional approval.
Commercial readiness is another issue. Replimune previously prepared manufacturing capacity and a launch organisation but announced job reductions and a significant scaling back of U.S. manufacturing after the April rejection. Approval on August 2 would require the company to rebuild momentum quickly.
The outcome will also affect RP2 and the broader RPx platform. Regulatory recognition of RP1 would validate the company’s oncolytic-virus approach, while another rejection could increase pressure to shift resources toward programmes supported by randomised evidence.
Can Replimune turn its third FDA review into the first approval for the RPx platform?
The latest acceptance has rescued RP1 from what appeared to be a potentially programme-ending rejection. Replimune now has an action date, an upcoming advisory committee and another opportunity to argue that prolonged responses justify access for patients with difficult-to-treat melanoma.
The company’s evidence is stronger than a superficial reading of a 33.6% response rate might suggest. Responses have been durable, complete responses have occurred and long-term survival appears encouraging.
The evidence is also weaker than a completed randomised trial. IGNYTE cannot provide a clean comparison against existing treatment, and the FDA has identified methodological factors that may have increased or complicated the reported response estimate.
The appropriate regulatory question is therefore not whether RP1 looks promising. It is whether the remaining uncertainty is acceptable for accelerated approval when patients face a serious disease and a confirmatory study can verify the benefit later.
Replimune’s third review has become a test of more than one melanoma therapy. It will show how the FDA balances urgent patient need, durable single-arm results and the requirement for controlled evidence when a company and the agency disagree over what constitutes sufficient proof.
Key takeaways from the FDA’s acceptance of Replimune’s latest RP1 resubmission
The FDA has accepted Replimune’s RP1 Biologics License Application resubmission as a Class 1 response and set August 2, 2026, as the target decision date. An advisory committee is expected in late July.
RP1 has already received two complete response letters. Both centred on whether the single-arm IGNYTE study provided reliable and adequately controlled evidence of effectiveness.
IGNYTE produced a 33.6% objective response rate, a 15% complete response rate and a median response duration of 24.8 months. Updated results showed median overall survival of 32.9 months and a three-year survival rate of 47.8%.
The FDA previously questioned response assessments, patient heterogeneity, historical comparisons and whether RP1’s contribution could be separated from nivolumab.
The latest resubmission has not been publicly linked to a new mature randomised efficacy dataset. The FDA appears to be reconsidering the total existing evidence alongside longer follow-up and a confirmatory-trial plan.
Replimune shares have more than doubled from their late-May level, but the stock remains exposed to a highly binary advisory committee and approval decision.
